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http://www.biomedcentral.com/1471-2407/14/953RESEARCH ARTICLE Open AccessCost-utility analysis of maintenance therapy with
gemcitabine or erlotinib vs observation with
predefined second-line treatment after
cisplatin–gemcitabine induction chemotherapy
for advanced NSCLC: IFCT-GFPC 0502-Eco phase
III study
Isabelle Borget1*, Maurice Pérol2,3, David Pérol2, Armelle Lavolé4, Laurent Greillier5,6, Pascal Dô7, Virginie Westeel8,
Jacky Crequit9, Hervé Léna10, Isabelle Monnet11, Hervé Le Caer12, Pierre Fournel13, Lionel Falchero14,
Michel Poudenx15, Fabien Vaylet16, Sylvie Chabaud2, Alain Vergnenegre17, Gérard Zalcman18,
Christos Chouaïd19 and on behalf of the IFCT-GFPC investigatorsAbstract
Background: The IFCT-GFPC 0502 phase III study reported prolongation of progression-free survival with gemcitabine or
erlotinib maintenance vs. observation after cisplatin–gemcitabine induction chemotherapy for advanced non-small-cell lung
cancer (NSCLC). This analysis was undertaken to assess the incremental cost-effectiveness ratio (ICER) of these strategies for
the global population and pre-specified subgroups.
Methods: A cost-utility analysis evaluated the ICER of gemcitabine or erlotinib maintenance therapy vs. observation, from
randomization until the end of follow-up. Direct medical costs (including drugs, hospitalization, follow-up examinations,
second-line treatments and palliative care) were prospectively collected per patient during the trial, until death, from the
primary health-insurance provider’s perspective. Utility data were extracted from literature. Sensitivity analyses were
conducted.
Results: The ICERs for gemcitabine or erlotinib maintenance therapy were respectively 76,625 and 184,733 euros per
quality-adjusted life year (QALY). Gemcitabine continuation maintenance therapy had a favourable ICER in patients
with PS = 0 (52,213 €/QALY), in responders to induction chemotherapy (64,296 €/QALY), regardless of histology
(adenocarcinoma, 62,292 €/QALY, non adenocarcinoma, 83,291 €/QALY). Erlotinib maintenance showed a
favourable ICER in patients with PS = 0 (94,908 €/QALY), in patients with adenocarcinoma (97,160 €/QALY) and
in patient with objective response to induction (101,186 €/QALY), but it is not cost-effective in patients with PS =1,
in patients with non-adenocarcinoma or with stable disease after induction chemotherapy.
Conclusion: Gemcitabine- or erlotinib-maintenance therapy had ICERs that varied as a function of histology, PS
and response to first-line chemotherapy.
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The National Institutes of Health estimated that $89 billion
were spent on cancer care in the US in 2007, and that the
total economic burden reached $219.2 billion when indirect
costs associated with lost productivity and premature death
were taken into account. Recent trends suggest that the
growth of cancer spending will accelerate, owing to costly
new treatments [1] and the increasing number of cancer pa-
tients. Lung cancer is the second most common malignancy
in the US and is the leading cause of cancer-related deaths
[2]. Non-small-cell lung cancers (NSCLC) represent 80% of
lung cancers and most patients already have advanced or
metastatic disease at diagnosis. Chemotherapy with 4 to 6 cy-
cles of a platinum-doublet is considered the standard of care
for first-line treatment of eligible patients with advanced
NSCLC. Most patients’ cancers progress after first-line ther-
apy and second-line chemotherapy is recommended for
those with performance-status (PS) 0 or 1 [3].
Maintenance therapy refers to therapy administered after
the initial chemotherapy regimen and it is continued or
maintained until progression. Multiple approaches are used,
including continuation of a portion of the first-line therapy
or “switching” to a non-cross–resistant chemotherapy [4].
The first studies conducted in this setting used chemother-
apy agents [5-8]. Gemcitabine given to advanced NSCLC
patients without progression after first-line treatment with a
gemcitabine-cisplatin combination significantly improved
progression-free survival (PFS), compared to the best pallia-
tive care, but the trial did not reach statistical significance
for overall survival (OS) [5]. Early docetaxel [8] for non-
progressive patients after a platinum doublet compared to
delayed docetaxel achieved a 3-months prolongation of PFS
with a not statistically significant increase in OS. In a simi-
larly designed trial on pemetrexed, PFS and OS were signifi-
cantly improved for the pemetrexed arm, with a survival
advantage of 2.8 months [7]. More recently, the results of a
phase III study [9] also showed a PFS benefit of continuing
pemetrexed after 4 cycles of cisplatin–pemetrexed for ad-
vanced non-squamous NSCLC. Maintenance with targeted
therapies also seems to be an attractive option, with
bevacizumab [10,11], cetuximab [12], erlotinib [13] and the
erlotinib–bevacizumab combination vs. bevacizumab [14]
yielding positive results. Recently, in a phase III trial, Pérol
et al. [15] compared gemcitabine or erlotinib maintenance
vs. observation for patients without disease progression after
platinum-based first-line chemotherapy, with a predefined
second-line therapy (pemetrexed), and found either gemcita-
bine or erlotinib to have a significantly improved PFS (pri-
mary endpoint), with a not significantly positive impact on
OS, possibly by a lack of power.
Maintenance therapy for advanced NSCLC not progres-
sing after a first cisplatin doublet became an option [3] but
the cost-effectiveness of this strategy has not been well-
established [16-20]. The published studies [16-19] hadseveral limitations: maintenance-period costs collected
retrospectively, second-line costs not collected [19,20] or
model-based study with no prospective recording of cost
data [18,19].
The purpose of this study was to conduct an economic
analysis of the IFCT-GFPC 0502 trial [15], in which each
patient’s consumed resources were collected prospectively
from randomization (after induction treatment) to the end
of the predefined pemetrexed second-line chemotherapy.
The aim of this cost-utility analysis was to assess the incre-
mental cost-effectiveness ratio (ICER) of either the gemcita-
bine or erlotinib strategy compared to observation, for all
NSCLC patients who received maintenance therapy (not
selected population), and in different patient subgroups, ac-
cording to PS (0 or 1), histology (adenocarcinoma or non-
adenocarcinoma) or response to first-line cisplatin-doublet
chemotherapy (stable disease or responder).
Methods
Patients and treatment
Patients’ data analyzed herein were obtained from the
phase III IFCT-GFPC 05-02 trial [ClinicalTrials.gov identi-
fier NCT00300586, 15]. All patients provided written in-
formed consent for participation in the study and consent
for tumor sample collection. The study was approved by
the Ethics Committee of Lyon, France and was conducted
in accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines. Briefly, the objective of that
study was to investigate gemcitabine or erlotinib mainten-
ance vs. observation for PS 0–1, advanced NSCLC pa-
tients, with no evidence of disease progression after
4 cycles of cisplatin–gemcitabine, and who received peme-
trexed as the predefined second-line therapy (Figure 1).
Of the 834 patients who received induction chemother-
apy, 464 (55.6%) were randomized. Median PFS was
significantly prolonged with gemcitabine (3.8 months)
or erlotinib (2.9 months) compared to observation
(1.9 months). The median PFS benefit seemed to be irre-
spective of histology for gemcitabine or erlotinib. Second-
line pemetrexed was administered in 84%, 74% and 75% of
the patients in the observation, gemcitabine and erlotinib
arms, respectively. Median OS was improved with gemci-
tabine (12.1 months) or erlotinib (11.4 months), although
not significantly, compared to observation (10.8 months).
Economic evaluation
The primary objective of this economic analysis was to
evaluate the ICERs of gemcitabine or erlotinib mainten-
ance therapy vs. observation. Results are expressed as cost
per quality-adjusted life years (QALY).
The natural course of NSCLC was divided into manage-
ment periods: maintenance therapy, second-line pemetrexed,
palliative care and death. During the maintenance period, pa-
tients were randomized to receive gemcitabine, erlotinib or
Figure 1 Design of the phase III IFCT-GFPC 05-02 trial. Legend: NSCLC, non-small-cell lung cancer; mets: metastasis; PD: progressive disease;
PS: performance-status; EGFR IHC: epidermal growth-factor receptor detected by immunohistochemistry; CT: chemotherapy. R: randomization.
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tus at this time, patients then received second-line peme-
trexed until their second disease progression, followed by
palliative care until death. Patients not given second-line
therapy directly received best supportive care until death.
Each patient’s time spent in each period was calculated with
the trial data.
Costs were estimated from the French health payer’s
perspective. They were computed from randomization
until the patient’s death or censoring date, and were
limited to direct medical costs. Each patient’s resource
consumptions were prospectively recorded in the case-
report form until the end of second-line chemotherapy.
That consumption included chemotherapy drugs (gem-
citabine, erlotinib and pemetrexed), hospitalization for
any reason and follow-up exams. Costs, expressed in
euros (€) were based on the national health-insurance
provider’s tariffs for diagnosis-related groups and na-
tional fees for ambulatory care, provided by the French
Ministry of Health and the national health-insurance
provider [21,22]. Table 1 shows unit prices and tariff
sources.
Costs incurred during the palliative period were de-
rived from a representative French nationwide sample of
428 patients, using chart review to assess the mean dir-
ect monthly cost of the first 18 months of NSCLC pa-
tient management [23]. Specifically, the costs included
outpatient and inpatient services, care provision at
skilled nursing facilities, outpatient and inpatient drugs
and other medications, nursing care organization, home
health visits and durable medical equipment. Assuming
a yearly increment of 3%, one month of palliative care
cost was 2,324 euros (2011 value). Transport and indir-
ect costs (like sick leave) were not included in theanalysis, because of insufficient data. No discount rate
was applied, given the short life expectancy of these
patients.
Utility
Self-assessed health state (or utility) scores measure the
individual’s preferences for specific outcomes, and are
used to calculate QALY. Because they were not directly
collected during the study, utility values were extracted
from a community population-based study on advanced
NSCLC in the UK [24] using the standard gamble inter-
view to assess quality of life. Utility scores differed ac-
cording to the period and the type of treatment received
(intravenous (IV) chemotherapy, oral chemotherapy,
none) (Table 1). Each patient’s QALY was then calcu-
lated, from randomization to death or censoring date, by
multiplying the duration of each period by the corre-
sponding period’s utility score.
Statistical and sensitivity analyses
Median PFS and OS were estimated using the Kaplan–
Meier method. The gemcitabine or erlotinib strategies
were compared to observation with the log-rank test. All
tests were two-sided.
An ICER was calculated as the ratio of the mean cost
difference to the mean effect difference between each
treatment strategy (gemcitabine or erlotinib) and
observation.
The uncertainty and robustness of the model were
evaluated in one-way sensitivity analyses, by varying
chemotherapy costs and utility values over a range of
likely values derived from confidence intervals (CI) or
reasonable ranges, while keeping the other parameters
constant.
Table 1 Unit cost and health-utility values used for the economic analysis
Category Tariff Origin
Costs
Gemcitabine €0.24/mg National reimbursement price [21]
Erlotinib 30-day supply (150 mg) €2174.70 National reimbursement price [21]
Pemetrexed €2.45/mg National reimbursement price [21]
GCS-F €185.80/inj National reimbursement price [21]
Epoetin €221.2/inj National reimbursement price [21]
DRG for transfusion €697.10 DRG 11th edition [22]
DRG for outpatient drug administration €400.70 DRG 11th edition [22]
Palliative care (per month) €2324 [€1627–€3021] Chouaïd [23]
Health-utility values
Maintenance therapy
Observation 0.693 [0.46–0.88] Nafees et al. [24]
IV chemotherapy (gemcitabine) 0.653 [0.26–0.78] Nafees et al. [24]
Oral chemotherapy (erlotinib) 0.673 [0.27–0.80] Nafees et al. [24]
Second-line therapy
IV chemotherapy (pemetrexed) 0.653 [0.26–0.78] Nafees et al. [24]
Palliative care 0.473 [0.19–0.56] Nafees et al. [24]
Death 0
Abbreviation: DRG diagnosis-related group.
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cedure with replacement based on the generation of
10,000 replications of the ratio using traditional prob-
abilistic sensitivity analysis (PSA), was used to obtain the
non-parametric 95% CI for the ICER. Estimations ob-
tained with the 10,000 bootstrap replications are pre-
sented in a radar screen format, with the X-axis showing
the difference in effectiveness (QALY) and the Y-axis
giving the cost difference between two strategies. Dots
represent the 10,000 replications. Bootstrapping was
used to determine the proportion of dots in each quad-
rant of the cost-effectiveness plane. The proportion of
replications below the €100,000 per QALY threshold was
also calculated. SAS software version 9.2 (SAS Inc, Cary,
NC) was used for statistical analyses.
Results
Between July 2006 and June 2009, among 834 patients
enrolled at 73 centers in France and who received cis-
platin–gemcitabine induction chemotherapy, 464 were
subsequently randomized to observation (n = 155) or
gemcitabine (n = 154) or erlotinib (n = 155) maintenance
therapy. Baseline characteristics were well-balanced among
treatment arms (Table 2). At the cut-off date for the pri-
mary endpoint (30 August 2010), median follow-up for all
patients was 25.6 months.
The result of the economic analysis showed that
the mean costs per patient of the maintenance period
for gemcitabine, erlotinib or observation maintenancestrategies were, respectively, €8,487, 10,551 and 702.
With total costs respectively estimated at €28,397,
31,928 and 22,734 for the gemcitabine, erlotinib and ob-
servation strategies, maintenance therapy represented
30%, 33% and 3% of total management cost of each
strategy (Table 3). Compared to observation, the ana-
lysis for the entire post-induction period showed that
gemcitabine and erlotinib ICERs were, respectively,
€76,625 [44,212 to 188,887] and €184,733 [94,559 to
1,186,736] per QALY. Estimations obtained with the
10,000 bootstrap replications showed that 94.9% of the
dots were located in the quadrant in which the gemcita-
bine strategy was more effective and more expensive
than observation, with an ICER ≤ €100,000 per QALY
for 69.5% of the cases (Figure 2). For erlotinib mainten-
ance, ICER was also more effective and more expensive
than observation in 85.4% of the simulations but ≤
€100,000 per QALY for only 12% of cases.
Subgroup analyses (Table 4) showed that ICERs were
favorable for the gemcitabine strategy, regardless of the
histologic type, with PS = 0 or for patients with an ob-
jective response at the onset of maintenance therapy.
The ICERs were also favorable for erlotinib in patients
with PS = 0, who had an objective response to induction
chemotherapy or with adenocarcinoma. Conversely, re-
gardless of the treatment strategy, maintenance was not
cost-effective for patients with PS = 1 or stable disease
after induction. Additionally, receiving erlotinib was not
cost-effective for patients with non-adenocarcInoma.
Table 2 Baseline characteristics of randomized patients
Characteristic Observation
n = 155
Gemcitabine
n = 154
Erlotinib
n = 155
Median age (range, years) 59.8 (37–72) 57.9 (29–71) 56.4 (36–71)
Gender, n (%)
Male 113 (72.9) 113 (73.4) 113 (72.9)
Female 42 (27.1) 41 (26.6) 42 (27.1)
ECOG PS at inclusion, n (%)
0 78 (50.3) 73 (47.4) 81 (52.3)
1 77 (49.7) 81 (52.6) 74 (47.7)
ECOG PS at randomization, n (%)
0 68 (44.2) 61 (40.1) 58 (37.9)
1 81 (52.6) 82 (53.9) 85 (55.6)
2 4 (2.6) 7 (4.6) 8 (5.2)
3 1 (0.6) 2 (1.3) 2 (1.3)
Unknown 1 (0.6) 2 (1.3) 2 (1.3)
Stage, n (%)
IIIB 14 (9.2) 14 (9.3) 11 (7.4)
IV 139 (90.8) 137 (90.7) 137 (92.6)
Unknown 2 (1.3) 3 (1.9) 7 (4.5)
Brain metastases, n (%) 1 (0.6) 5 (3.2) 2 (1.3)
Smoking status, n (%)
Current and former smokers 143 (92.3) 137 (89) 138 (89.0)
Never smoker* 12 (7.7) 17 (11.0) 17 (11)
Histology, n (%)
Adenocarcinoma 103 (66.5) 101 (65.6) 97 (62.6)
Squamous cell carcinoma 30 (19.4) 34 (22.1) 27 (17.4)
Unknown 22 (14.2) 19 (12.3) 31 (20)
Response to induction chemotherapy, n (%)
Objective response 82 (52.9) 81 (52.6) 82 (52.9)
Stable disease 73 (47.1) 73 (47.4) 73 (47.1)
Abbreviations: ECOG Eastern Cooperative Oncology Group, PS performance status.
*Defined as consumption of < 100 cigarettes throughout one’s entire lifetime.
Table 3 Mean cost (in euros) and mean effectiveness (in QALY) per patient for each maintenance strategy, during the
different management periods after induction chemotherapy
Observation (n = 155) Gemcitabine (n = 154) Erlotinib (n = 155)
Parameter Cost QALY Cost QALY Cost QALY
Maintenance €702 0.202 €8,487 0.256 €10,551 0.241
Second-line €7,449 0.114 €6,412 0.103 €6,637 0.103
Palliative care €14,582 0.229 €13,497 0.260 €14,741 0.251
Total €22,734 0.545 €28,397 0.619 €31,928 0.595
Difference from observation – – €5,663 0.074 €9,195 0.050
ICER – – 76,625 [44,212 – 188,887] 184,733 [94,559 – 1,186,736]
Legend: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
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Figure 2 Multivariate probabilistic sensitivity analysis (results of a 10 000-replication simulation). A. Gemcitabine v observation, B.
Erlotinib v observation.
Borget et al. BMC Cancer 2014, 14:953 Page 6 of 10
http://www.biomedcentral.com/1471-2407/14/953The results of the one-way sensitivity analyses (Table 5)
indicate that the main ICER drivers were the costs of
maintenance treatments and health-utility values. In
contrast, second-line medications and palliative care
costs had only a weak impact on ICER.
Discussion and conclusion
This analysis of gemcitabine or erlotinib maintenance
therapy vs. observation with a fixed second-line therapy
for advanced NSCLC found a respective ICER of €76,625and €184,733 per QALY but they varied widely depending
on histology, PS and response to induction therapy. Gem-
citabine for patients with PS = 0, objective response to in-
duction, regardless of the histology, and erlotinib for
patients with PS = 0, responses to induction or adenocar-
cinoma had the more favourable ICER.
Few economic studies on maintenance treatments for
advanced NSCLC have been published [16-20]. Differ-
ences in methods, currency and economic outcomes, hin-
dered direct comparisons with our results. In particular a
Table 4 Incremental cost-effectiveness ratio (ICER, expressed in euros per QALY), of the different patient subgroups
Group Gemcitabine (n = 154) Erlotinib (n = 155)
All patients 76,625 184,733
Performance-status
0 52,213 94,908
1 372,624 –*
Histology
Adenocarcinoma 62,292 97,160
Squamous cell carcinoma or unknown 83,291 –*
Response to induction therapy
Objective response 64,296 101,186
Stable disease 153,337 –*
Incremental cost-effectiveness ratios (ICER) are expressed in euros/quality adjusted-life years (QALY).
*The ICER was not calculated because the tested strategy does not appear to be more effective than observation.
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gained (LYG), which is not directly comparable to cost per
QALY.
From the US primary health-insurance provider per-
spective, using the JMEN trial’s data [7], Medicare reim-
bursement rates and a retrospective claims database, Klein
et al. [16] calculated the ICER of pemetrexed maintenance
compared to observation and found, regardless of histo-
logic subtype, an ICER of US$205,597 per life-year gainedTable 5 Incremental cost-effectiveness ratio (expressed in eur
Parameter value Gem
Base case
Gemcitabine tariff
–30%
Erlotinib tariff
–30%
Pemetrexed tariff
–30%
Palliative care cost
€1,627 per month
€3,021 per month
Utility score under observation
–10%
+10%
Utility score under IV chemotherapy
–10%
+10%
Utility score under oral chemotherapy
–10%
+10%
Incremental cost-effectiveness ratios (ICER) are expressed in euros/quality adjusted-
univariate analysis.
Legend: IV: intravenous.(LYG). This difference can mostly be explained by the cost
of pemetrexed, which is much more expensive than gem-
citabine. As in our study, their ICER varied according to
histology, with US$122,371 per LYG for patients with
non-squamous cell NSCLC. Using the same JMEN trial
data [7] and based on the evidence submitted by the
manufacturer, the National Institute for Health and Clin-
ical Excellence (NICE) calculated an ICER of £47,000 per
QALY for the non-squamous NSCLC population [25].os per QALY) in the univariate analysis
citabine (n = 154) Erlotinib (n = 155)
76,625 184,733
47,132 –
– 125,957
79,749 188,212
81,021 183,772
72,213 185,680
117,197 307 149
57,136 130,727
€117,197 –
€57,136 –
– €366,092
– €124,060
life years (QALY). The sign “-” was used when the ICER was not affected by the
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health insurers vantage point [19], the ICER for peme-
trexed maintenance was about US$109,024 per LYG
and US$203,022 per QALY for all histologic types, again
more favorable for non-squamous types (respectively,
US$80,563 per LYG and US$150,115 per QALY).
Any studies have analyzed ICER according to the re-
sponse to induction chemotherapy. In contrast to our
findings, Vergnenègre et al. [26] conducted a model-based
study using SATURN [13] data and found that the erloti-
nib cost per LYG versus best palliative care was €39,783,
€46,931 and €27,885 in France, Germany, and Italy, re-
spectively. This difference is mostly attributable to the
methodology applied (retrospective analysis and modeliza-
tion of second-line therapy costs). NICE analysis of the
same strategy (erlotinib maintenance for patients with ad-
vanced NSCLC and stable disease after four cycles of
platinum-induction therapy) calculated respective ICER of
£44,812 and £68,120 per QALY for squamous and non-
squamous NSCLC patients [27]. All these observations
are compatible with our results for the total population,
but their methodologies do not allow a precise analysis of
the benefit of maintenance therapy according to import-
ant clinical characteristics, like PS and the response to in-
duction therapy.
The latest guidelines recommend that quality of life be
taken into account when considering treatment for
NSCLC [28]. Taking account for the NSCLC burden in
terms of health-related quality of life, little information
is available on patients’ or society’s preferences with re-
spect to disease states. We used data from Nafees et al.
[24], who adapted existing health-state descriptions of
metastatic breast cancer to evaluate the utilities of pa-
tients receiving second-line treatment for NSCLC. Each
health state describes the symptom burden of a disease
and its functional impact.
Our study had several strengths: a head-to-head com-
parative trial, prospective cost collection of data, patient
cohort representative of those able to receive maintenance
therapy in the routine clinical setting and a pre-specified
second-line treatment administered in more than 75% of
the patients in each arm. A subgroup analysis was per-
formed as currently, systemic cytotoxic chemotherapy re-
mains the first-line treatment for most patients with stage
IV NSCLC, but preferred treatments are now defined by
histology and based on the presence of specific molecular
abnormalities [29]. It showed that ICERs of gemcitabine
versus observation were more favorable in patients with
PS = 0 or those who responded to induction compared to
patients with PS = 1 or stabilization of disease after induc-
tion. For erlotinib arm, the tested strategy appeared to be
not cost effective compared to observation for patients PS= 1,
squamous histology or patients with stable disease as the
better response after induction. However, it also had somelimitations. First, costs were identified prospectively
only during the active treatment periods, i.e. until the
end of the second-line chemotherapy. Management costs
after the end of active treatments were only derived from
retrospective data of a 2004 national database. Some pa-
tients might have received and eventually benefit from a
third-line chemotherapy, and we hypothesized that their
expenditures for these chemotherapies would be identical
in the 3 arms, and would not impact on the final results.
Second, our analysis was limited to direct NSCLC-related
medical costs: indirect costs, e.g. lost productivity and
caregiver salaries, were not included. Third, the expression
of utilities reflects the value from society’s perspective ra-
ther than that of the patients involved, since no prospect-
ive utility data were collected. Another point was that
gemcitabine is now generic in most of the countries which
likely means its costs were overestimated for gemcitabine
strategy.
Finally at the time of the trial, pemetrexed was used for
both squamous and non-squamous histology but only in
second line setting. Now, pemetrexed is approved also for
1st line advanced NSCLC, but restricted to non-squamous
histology. Therefore the trial population may be different
than a potential gemcitabine or erlotinib maintenance
population would be today.
Despite these limitations, the results of our analyses
showed that gemcitabine or erlotinib maintenance therapy
had acceptable ICER for certain subgroups, that they var-
ied widely as a function of histology, PS and the response
to first-line chemotherapy. These factors must be taken
into consideration to better define the indications for
NSCLC management.
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